KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
August 08, 2017 07:30 ET
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Aug. 08, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results
July 27, 2017 16:01 ET
|
KalVista Pharmaceuticals, Inc.
– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance – – Intravitreal Diabetic Macular Edema Phase 2 On Track to Initiate in 2017 – CAMBRIDGE,...
KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference
June 01, 2017 07:30 ET
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, June 01, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Reports Fiscal Third Quarter Results
March 16, 2017 16:15 ET
|
KalVista Pharmaceuticals, Inc.
– Continuing to Develop a Portfolio of Oral Plasma Kallikrein Inhibitors for HAE –– Intravitreal DME Program Remains on Track for Phase 2 in 2017 –– Company Expects to be Well-Funded Through...